《大行報告》美銀證券下調國壽(02628.HK)目標價至22.1元 評級「買入」
美銀證券報告指,國壽(02628.HK)公布首季純利171億元人民幣,按年倒退34%,主要由於投資收益在高基數影響下大減,另外亦於季內提升儲備。首季國壽保費收入按年增長13%,跑贏同業,首年標準保費收入按年增長14%。新業務價值增長8.3%,同為業內表現最佳。該行表示,主要是由於國壽較早開展其「開門紅」銷售。惟在相關因素過去後,相信國壽亦將面對同業所面對的挑戰,下調國壽今年新業務價值增長預測至7.3%,2020年至2022年盈測亦下調6%至7%,目標價自23.5元下調至22.1元,評級維持「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.